Top

Published in:

01-05-2007

RET Signaling in Endocrine Tumors: Delving Deeper into Molecular Mechanisms

Authors: Andrea Z. Lai, Taranjit S. Gujral, Lois M. Mulligan

Published in: Endocrine Pathology | Issue 2/2007

Abstract

The rearranged during transfection (RET) proto-oncogene encodes a receptor tyrosine kinase that is implicated in the development of endocrine tumors of the thyroid and adrenal glands. In humans, activating RET mutations are found in the inherited cancer syndrome multiple endocrine neoplasia 2 and in sporadic medullary and papillary thyroid carcinomas. The specific type and location of RET mutations are strongly correlated with the disease phenotype and have both diagnostic and prognostic value. Recent advances in the molecular characterization of the RET receptor and its mutants have begun to define the mechanisms underlying the transforming ability of the different RET mutant forms. This information has revealed key functional features of these mutant proteins that distinguish the different clinically recognized mutations and provide clues as to the functional origins of the phenotypes associated with specific RET mutations. The elucidation of molecular mechanisms involved in RET-mediated transformation is a key step in the development of much needed therapeutics that target RET’s oncogenic properties. Recent advances have begun to provide a deeper understanding of the receptor’s function, and dysfunction, in human tumors that may guide this process.

Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60:557–63, 1990.PubMedCrossRef

Mulligan LM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458–60, 1993.PubMedCrossRef

Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H, Hiai H. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 3:571–8, 1988.PubMed

Avantaggiato V, Dathan NA, Grieco M, Fabien N, Lazzaro D, Fusco A, et al. Developmental expression of the RET protooncogene. Cell Growth Differ 5:305–11, 1994.PubMed

Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, Pachnis V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 367:380–3, 1994.PubMedCrossRef

Takahashi M, Cooper G. ret transforming gene encodes a fusion protein homologous to tyrosine kinases. Mol Cell Biol 7:1378–85, 1987.PubMed

Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3:383–94, 2002.PubMedCrossRef

Kawamoto Y, Takeda K, Okuno Y, Yamakawa Y, Ito Y, Taguchi R, et al. Identification of RET autophosphorylation sites by mass spectrometry. J Biol Chem 279:14213–24, 2004.PubMedCrossRef

Iwashita T, Asai N, Murakami H, Matsuyama M, Takahashi M. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation. Oncogene 12:481–7, 1996.PubMed

10.

Liu X, Vega QC, Decker RA, Pandey A, Worby CA, Dixon JE. Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities. J Biol Chem 271:5309–12, 1996.PubMedCrossRef

11.

Knowles PP, Murray-Rust J, Kjaer S, Scott RP, Hanrahan S, Santoro M, et al. Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem 281:33577–87, 2006.PubMedCrossRef

12.

Kodama Y, Asai N, Kawai K, Jijiwa M, Murakumo Y, Ichihara M, et al. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Sci 96:143–8, 2005.PubMedCrossRef

13.

Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 16:441–67, 2005.PubMedCrossRef

14.

Koper JW, Lamberts SW. Sporadic endocrine tumours and their relationship to the hereditary endocrine neoplasia syndromes. Eur J Clin Invest 30:493–500, 2000.PubMedCrossRef

15.

Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium. JAMA 276:1575–9, 1996.PubMedCrossRef

16.

Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 5:367–75, 2005.PubMedCrossRef

17.

Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJM, et al. Genotype–phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 238:343–6, 1995.PubMedCrossRef

18.

Lindahl M, Poteryaev D, Yu L, Arumae U, Timmusk T, Bongarzone I, et al. Human glial cell line-derived neurotrophic factor receptor alpha 4 is the receptor for persephin and is predominantly expressed in normal and malignant thyroid medullary cells. J Biol Chem 276:9344–51, 2001.PubMedCrossRef

19.

Gimm O, Dziema H, Brown J, Hoang-Vu C, Hinze R, Dralle H, et al. Over-representation of a germline variant in the gene encoding RET co-receptor GFRα-1 but not GFRα-2 or GFRα-3 in cases with sporadic medullary thyroid carcinoma. Oncogene 20:2161–70, 2001.PubMedCrossRef

20.

Frisk T, Farnebo F, Zedenius J, Grimelius L, Hoog A, Wallin G, et al. Expression of RET and its ligand complexes, GDNF/GFRalpha-1 and NTN/GFRalpha-2, in medullary thyroid carcinomas. Eur J Endocrinol 142:643–9, 2000.PubMedCrossRef

21.

Le Hir H, Charlet-Berguerand N, Gimenez-Roqueplo A, Mannelli M, Plouin P, de Franciscis V, et al. Relative expression of the RET9 and RET51 isoforms in human pheochromocytomas. Oncology 58:311–8, 2000.PubMedCrossRef

22.

Jimenez C, Cote G, Arnold A, Gagel RF. Review: should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol Metab 91:2851–8, 2006.PubMedCrossRef

23.

Lindor NM, Honchel R, Khosla S, Thibodeau SN. Mutations of the RET protooncogene in sporadic pheochromocytomas. J Clin Endocrinol Metab 80:627–9, 1995.PubMedCrossRef

24.

van der Harst E, de Krijger RR, Bruining HA, Lamberts SW, Bonjer HJ, Dinjes WN, et al. Prognostic value of RET proto-oncogene point mutations in malignant and benign, sporadic phaeochromocytomas. Int J Cancer 79:537–40, 1998.PubMedCrossRef

25.

Komminoth P, Roth J, Muletta-Feurer S, Saremaslani P, Seelentag WK, Heitz PU. RET proto-oncogene point mutations in sporadic neuroendocrine tumors. J Clin Endocrinol Metab 81:2041–6, 1996.PubMedCrossRef

26.

Padberg B-C, Schröder S, Jochum W, Kastendieck H, Roth J, Heitz PU, et al. Absence of RET proto-oncogene point mutations in sporadic hyperplastic and neoplastic lesions of the parathyroid gland. Am J Pathol 147:1600–7, 1995.PubMed

27.

Morrison PJ, Nevin NC. Multiple endocrine neoplasia type 2B (mucosal neuroma syndrome, Wagenmann–Froboese syndrome). J Med Genet 33:779–82, 1996.PubMedCrossRef

28.

Brauckhoff M, Gimm O, Weiss CL, Ukkat J, Sekulla C, Brauckhoff K, et al. Multiple endocrine neoplasia 2B syndrome due to codon 918 mutation: clinical manifestation and course in early and late onset disease. World J Surg 28:1305–11, 2004.PubMedCrossRef

29.

Farndon JR, Leight GS, Dilley WG, Baylin SB, Smallridge RC, Harrison TS, et al. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg 73:278–81, 1986.PubMedCrossRef

30.

Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JBJ, Gardner E, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nature Genet 6:70–4, 1994.PubMedCrossRef

31.

Ito S, Iwashita T, Asai N, Murakami H, Iwata Y, Sobue G, et al. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung’s disease phenotype. Cancer Res 57:2870–2, 1997.PubMed

32.

Eng C, Thomas GA, Neuberg DS, Mulligan LM, Healey CS, Hougton C, et al. Mutation of the RET proto-oncogene is correlated with RET immunostaining in subpopulations of cells in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 83:4310–3, 1998.PubMedCrossRef

33.

Eng C, Mulligan LM. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours and Hirschsprung disease. Hum Mutat 9:97–109, 1997.PubMedCrossRef

34.

Eng C, Mulligan LM, Healey CS, Houghton C, Frilling A, Raue F, et al. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res 56:2167–70, 1996.PubMed

35.

Takahashi M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 12:361–73, 2001.PubMedCrossRef

36.

Asai N, Iwashita T, Matsuyama M, Takahashi M. Mecahanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 15:1613–9, 1995.PubMed

37.

Kjaer S, Kurokawa K, Perrinjaquet M, Abrescia C, Ibanez CF. Self-association of the transmembrane domain of RET underlies oncogenic activation by MEN2A mutations. Oncogene 25:7086–95, 2006.PubMedCrossRef

38.

Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267:381–3, 1995.PubMedCrossRef

39.

Tansey MG, Baloh RH, Milbrandt J, Johnson EM. GFRalpha-mediated localization of RET to lipid rafts is required for effective downstream signaling, differentiation, and neuronal survival. Neuron 25:611–23, 2000.PubMedCrossRef

40.

Pierchala BA, Milbrandt J, Johnson EM, Jr. Glial cell line-derived neurotrophic factor-dependent recruitment of Ret into lipid rafts enhances signaling by partitioning Ret from proteasome-dependent degradation. J Neurosci 26:2777–87, 2006.PubMedCrossRef

41.

Paratcha G, Ledda F, Baars L, Coulpier M, Besset V, Anders J, et al. Released GFRalpha1 potentiates downstream signaling, neuronal survival, and differentiation via a novel mechanism of recruitment of c-Ret to lipid rafts. Neuron 29:171–84, 2001.PubMedCrossRef

42.

Freche B, Guillaumot P, Charmetant J, Pelletier L, Luquain C, Christiansen D, et al. Inducible dimerization of RET reveals a specific AKT deregulation in oncogenic signalling. J Biol Chem 280:36584–91, 2005.PubMedCrossRef

43.

Drosten M, Hilken G, Bockmann M, Rodicker F, Mise N, Cranston AN, et al. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. J Natl Cancer Inst 96:1231–9, 2004.PubMedCrossRef

44.

Richardson DS, Lai AZ, Mulligan LM. RET ligand-induced internalization and its consequences for downstream signaling. Oncogene 25:3206–11, 2006.PubMedCrossRef

45.

Yang J, Runeberg-Roos P, Leppanen VM, Saarma M. The mouse soluble GFRalpha4 receptor activates RET independently of its ligand persephin. Oncogene 26:3892–8, 2007.PubMedCrossRef

46.

Vanhorne JB, Andrew SD, Harrison KJ, Taylor SA, Thomas B, McDonald TJ, et al. A model for GFR alpha 4 function and a potential modifying role in multiple endocrine neoplasia 2. Oncogene 24:1091–7, 2005.PubMedCrossRef

47.

Machens A, Brauckhoff M, Holzhausen HJ, Thanh PN, Lehnert H, Dralle H. Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 90:3999–4003, 2005.PubMedCrossRef

48.

Gujral TS, Singh VK, Jia Z, Mulligan LM. Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B. Cancer Res 66:10741–9, 2006.PubMedCrossRef

49.

Mise N, Drosten M, Racek T, Tannapfel A, Putzer BM. Evaluation of potential mechanisms underlying genotype–phenotype correlations in multiple endocrine neoplasia type 2. Oncogene 25:6637–47, 2006.PubMedCrossRef

50.

Bongarzone I, Vigano E, Alberti L, Borrello MG, Pasini B, Greco A, et al. Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation. Oncogene 16:2295–301, 1998.PubMedCrossRef

51.

Cranston AN, Carniti C, Oakhill K, Radzio-Andzelm E, Stone EA, McCallion AS, et al. RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B. Cancer Res 66:10179–87, 2006.PubMedCrossRef

52.

Bocciardi R, Mograbi B, Pasini B, Borrello MG, Pierotti MA, Bourget I, et al. The multiple endocrine neoplasia type 2B mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck. Oncogene 15:2257–65, 1997.PubMedCrossRef

53.

Songyang Z, Carraway KL, Eck MJ, Harrison SC, Feldman RA, Mohammadi M, et al. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 373:536–9, 1995.PubMedCrossRef

54.

Yuan ZL, Guan YJ, Wang L, Wei W, Kane AB, Chin YE. Central role of the threonine residue within the p+1 loop of receptor tyrosine kinase in STAT3 constitutive phosphorylation in metastatic cancer cells. Mol Cell Biol 24:9390–400, 2004.PubMedCrossRef

55.

Plaza Menacho I, Koster R, van der Sloot AM, Quax WJ, Osinga J, van der Sluis T, et al. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. Cancer Res 65:1729–37, 2005.PubMedCrossRef

56.

Read RD, Goodfellow PJ, Mardis ER, Novak N, Armstrong JR, Cagan RL. A Drosophila model of multiple endocrine neoplasia type 2. Genetics 171:1057–81, 2005.PubMedCrossRef

57.

Gimm O, Marsh DJ, Andrew SD, Frilling A, Dahia PLM, Mulligan LM, et al. Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab 82:3902–4, 1997.PubMedCrossRef

58.

Smith DP, Houghton C, Ponder BAJ. Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene 15:1213–7, 1997.PubMedCrossRef

59.

Elisei R, Cosci B, Romei C, Agate L, Piampiani P, Miccoli P, et al. Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition. J Clin Endocrinol Metab 89:5823–7, 2004.PubMedCrossRef

60.

Iwashita T, Kato M, Murakami H, Asai N, Ishiguro Y, Ito S, et al. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene 18:3919–22, 1999.PubMedCrossRef

61.

Schuringa JJ, Wojtachnio K, Hagens W, Vellenga E, Buys CH, Hofstra R, et al. MEN2A-RET-induced cellular transformation by activation of STAT3. Oncogene 20:5350–8, 2001.PubMedCrossRef

62.

Plaza-Menacho I, van der Sluis T, Hollema H, Gimm O, Buys CH, Magee AI, et al. Ras/ERK1/2-mediated STAT3 Serine 727 phosphorylation by familiar medullary thyroid carcinoma-associated RET mutants induces full activation of STAT3 and is required for c-fos promoter activation, cell mitogenicity and transformation. J Biol Chem 282:6415–24, 2007.PubMedCrossRef

63.

Gimm O, Ukkat J, Niederle BE, Weber T, Thanh PN, Brauckhoff M, et al. Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia 2A-related RET mutations not affecting codon 634. World J Surg 28:1312–6, 2004.PubMedCrossRef

64.

Pasini A, Geneste O, Legrand P, Schlumberger M, Rossel M, Fournier L, et al. Oncogenic activation by two distinct FMTC mutations affecting the tyrosine kinase domain. Oncogene 15:393–402, 1997.PubMedCrossRef

65.

Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, et al. Multiple endocrine neoplasia type 2: evaluation of the genotype–phenotype relationship. Arch Surg 138:409–16, 2003.PubMedCrossRef

66.

Lesueur F, Cebrian A, Cranston A, Leyland J, Faid TM, Clements MR, et al. Germline homozygous mutations at codon 804 in the RET protooncogene in medullary thyroid carcinoma/multiple endocrine neoplasia type 2A patients. J Clin Endocrinol Metab 90:3454–7, 2005.PubMedCrossRef

67.

Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98:326–34, 2006.PubMed

68.

Carlomagno F, Guida T, Anaganti S, Vecchio G, Fusco A, Ryan AJ, et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 23:6056–63, 2004.PubMedCrossRef

69.

Drosten M, Putzer BM. Mechanisms of disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. Nat Clin Pract Oncol 3:564–74, 2006.PubMedCrossRef

70.

Fagin JA. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 183:249–56, 2004.PubMedCrossRef

71.

Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292–306, 2006.PubMedCrossRef

72.

Bunone G, Uggeri M, Mondellini P, Pierotti MA, Bongarzone I. RET receptor expression in thyroid follicular epithelial cell-derived tumors. Cancer Res 60:2845–9, 2000.PubMed

73.

Smida J, Salassidis K, Hieber L, Zitzelsberger H, Kellerer AM, Demidchik EP, et al. Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus. Int J Cancer 80:32–38, 1999.PubMedCrossRef

74.

Santoro M, Melillo RM, Fusco A. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol 155:645–53, 2006.PubMedCrossRef

75.

Melillo RM, Cirafici AM, De Falco V, Bellantoni M, Chiappetta G, Fusco A, et al. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Am J Pathol 165:511–21, 2004.PubMed

76.

Ciampi R, Nikiforov YE. Ret/Ptc rearrangements and braf mutations in thyroid tumorigenesis. Endocrinology 148:936–41, 2007.PubMedCrossRef

77.

Jhiang SM. The RET proto-oncogene in human cancers. Oncogene 19:5590–7, 2000.PubMedCrossRef

78.

Nikiforova MN, Stringer JR, Blough R, Medvedovic M, Fagin JA, Nikiforov YE. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science 290:138–41, 2000.PubMedCrossRef

79.

Gandhi M, Medvedovic M, Stringer JR, Nikiforov YE. Interphase chromosome folding determines spatial proximity of genes participating in carcinogenic RET/PTC rearrangements. Oncogene 25:2360–6, 2006.PubMedCrossRef

80.

Santoro M, Melillo RM, Grieco M, Berlingieri MT, Vecchio G, Fusco A. The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. Cell Growth Differ 4:77–84, 1993.PubMed

81.

Santoro M, Dathan NA, Berlingieri MT, Bongarzone I, Paulin C, Grieco M, et al. Molecular characterization of RET/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. Oncogene 9:509–16, 1994.PubMed

82.

Jhiang SM, Sagartz JE, Tong Q, Parker-Thornburg J, Capen CC, Cho JY, et al. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 137:375–8, 1996.PubMedCrossRef

83.

Powell DJ Jr, Russell J, Nibu K, Li G, Rhee E, Liao M, et al. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res 58:5523–8, 1998.PubMed

84.

Santoro M, Chiappetta G, Cerrato A, Salvatore D, Zhang L, Manzo G, et al. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene 12:1821–6, 1996.PubMed

85.

Viglietto G, Chiappetta G, Martinez-Tello FJ, Fukunaga FH, Tallini G, Rigopoulou D, et al. RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene 11:1207–10, 1995.PubMed

86.

Nakashima M, Takamura N, Namba H, Saenko V, Meirmanov S, Matsumoto N, et al. RET oncogene amplification in thyroid cancer: correlations with radiation-associated and high-grade malignancy. Hum Pathol 38:621–8, 2007.PubMedCrossRef

87.

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 417:949–54, 2002.PubMedCrossRef

88.

Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245–62, 2005.PubMedCrossRef

89.

Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454–7, 2003.PubMed

90.

Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 115:1068–81, 2005.PubMedCrossRef

91.

Knauf JA, Kuroda H, Basu S, Fagin JA. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene 22:4406–12, 2003.PubMedCrossRef

92.

Takahashi M, Iwashita T, Santoro M, Lyonnet S, Lenoir GM, Billaud M. Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function? Hum Mutat 13:331–6, 1999.PubMedCrossRef

93.

Frank-Raue K, Höppner W, Frilling A, Kotzerke J, Dralle H, Haase R, et al. Mutations of the RET proto-oncogene in German MEN families: relation between genotype and phenotype. J Clin Endocrinol Metab 81:1780–3, 1996.PubMedCrossRef

94.

Schuffenecker I, Virally-Monod M, Brohet R, Goldgar D, Conte-Devolx B, Leclerc L, et al. Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs a Calcitonine. J Clin Endocrinol Metab 83:487–91, 1998.PubMedCrossRef

95.

Lindahl M, Timmusk T, Rossi J, Saarma M, Airaksinen MS. Expression and alternative splicing of mouse Gfra4 suggest roles in endocrine cell development. Mol Cell Neurosci 15:522–33, 2000.PubMedCrossRef

96.

Powers JF, Brachold JM, Tischler AS. Ret protein expression in adrenal medullary hyperplasia and pheochromocytoma. Endocr Pathol 14:351–61, 2003.PubMedCrossRef

97.

Tsuzuki T, Takahashi M, Asai N, Iwashita T, Matsuyama M, Asai J. Spatial and temporal expression of the ret proto-oncogene product in embryonic, infant and adult rat tissues. Oncogene 10:191–8, 1995.PubMed

98.

Takaya K, Yoshimasa T, Arai H, Tamura N, Miyamoto Y, Itoh H, et al. Expression of the RET proto-oncogene in normal human tissues, pheochromocytomas, and other tumors of neural crest origin. J Mol Med 74:617–21, 1996.PubMedCrossRef

99.

Takaya K, Yoshimasa T, Arai H, Tamura N, Miyamoto Y, Itoh H, et al. The RET proto-oncogene in sporadic pheochromocytomas. Intern Med 35:449–52, 1996.PubMed

100.

Powers JF, Schelling KH, Tischler AS. Chromaffin cell mitogenesis by neurturin and glial cell line-derived neurotrophic factor. Neuroscience 108:341–9, 2001.PubMedCrossRef

Title: RET Signaling in Endocrine Tumors: Delving Deeper into Molecular Mechanisms
Authors: Andrea Z. Lai
Taranjit S. Gujral
Lois M. Mulligan
Publication date: 01-05-2007
Publisher: Humana Press Inc
Published in: Endocrine Pathology / Issue 2/2007
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI: https://doi.org/10.1007/s12022-007-0009-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2007

AIP Mutations are not Identified in Patients with Sporadic Pituitary Adenomas

The Tenth Meeting of the International Pituitary Club

Differential Expression of the Five Somatostatin Receptor Subtypes in Human Benign and Malignant Insulinomas – Predominance of Receptor Subtype 4

Pituitary Adenoma with Tumoral Granulomatous Reaction

The Cytoplasmic Expression of MUC1 in Papillary Thyroid Carcinoma of Different Histological Variants and its Correlation with Cyclin D1 Overexpression

A Large Sellar Granular Cell Tumor in a 21-year-old Woman

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials